Vertex Pharmaceuticals Incorporated
VRTX
$472.27
$10.142.19%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.21% | -12.67% | 129.09% | -426.81% | 13.50% |
| Total Depreciation and Amortization | 127.23% | -59.96% | -1.48% | 0.93% | 13.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 111.93% | 62.97% | 314.96% | 13.22% | -47.05% |
| Change in Net Operating Assets | 52.07% | -455.68% | 165.24% | -286.70% | 115.41% |
| Cash from Operations | 40.08% | -57.32% | 136.49% | -387.28% | 456.95% |
| Capital Expenditure | 56.05% | -36.78% | 1.88% | -0.88% | -17.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.93% | -160.19% | 28.98% | 80.91% | -149.64% |
| Cash from Investing | 93.21% | -136.18% | 24.95% | 78.30% | -140.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 75.93% | 60.58% | -3.79% | -10.00% |
| Issuance of Common Stock | -51.31% | 308.33% | -84.73% | 225.44% | -63.58% |
| Repurchase of Common Stock | -63.83% | -8.64% | 2.35% | -9.90% | -138.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11.11% | 0.00% | 0.00% | -74.29% | 333.33% |
| Cash from Financing | -73.88% | -0.98% | -8.06% | -0.31% | -198.41% |
| Foreign Exchange rate Adjustments | 164.48% | -307.46% | 1,012.00% | 83.97% | -156.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.75% | -202.86% | 114.35% | -280.61% | -61.61% |